Logo image of SALME.OL

SALMON EVOLUTION ASA (SALME.OL) Stock Fundamental Analysis

OSL:SALME - Euronext Oslo - NO0010892094 - Common Stock - Currency: NOK

6.09  0 (0%)

Fundamental Rating

3

Taking everything into account, SALME scores 3 out of 10 in our fundamental rating. SALME was compared to 55 industry peers in the Food Products industry. Both the profitability and financial health of SALME have multiple concerns. SALME shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SALME has reported negative net income.
In the past year SALME had a positive cash flow from operations.
In the past 5 years SALME always reported negative net income.
SALME had negative operating cash flow in 4 of the past 5 years.
SALME.OL Yearly Net Income VS EBIT VS OCF VS FCFSALME.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M

1.2 Ratios

SALME has a Return On Assets of -2.87%. This is in the lower half of the industry: SALME underperforms 72.73% of its industry peers.
SALME has a worse Return On Equity (-4.54%) than 72.73% of its industry peers.
Industry RankSector Rank
ROA -2.87%
ROE -4.54%
ROIC N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
SALME.OL Yearly ROA, ROE, ROICSALME.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

SALME has a better Gross Margin (65.28%) than 94.55% of its industry peers.
In the last couple of years the Gross Margin of SALME has declined.
The Profit Margin and Operating Margin are not available for SALME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
SALME.OL Yearly Profit, Operating, Gross MarginsSALME.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

SALME does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SALME has more shares outstanding
Compared to 5 years ago, SALME has more shares outstanding
The debt/assets ratio for SALME has been reduced compared to a year ago.
SALME.OL Yearly Shares OutstandingSALME.OL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
SALME.OL Yearly Total Debt VS Total AssetsSALME.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 1.43, we must say that SALME is in the distress zone and has some risk of bankruptcy.
SALME's Altman-Z score of 1.43 is on the low side compared to the rest of the industry. SALME is outperformed by 69.09% of its industry peers.
SALME has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.39, SALME is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z 1.43
ROIC/WACCN/A
WACC7.97%
SALME.OL Yearly LT Debt VS Equity VS FCFSALME.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

SALME has a Current Ratio of 1.80. This is a normal value and indicates that SALME is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.80, SALME is doing good in the industry, outperforming 72.73% of the companies in the same industry.
A Quick Ratio of 1.29 indicates that SALME should not have too much problems paying its short term obligations.
SALME's Quick ratio of 1.29 is fine compared to the rest of the industry. SALME outperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.8
Quick Ratio 1.29
SALME.OL Yearly Current Assets VS Current LiabilitesSALME.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.43% over the past year.
The Revenue has grown by 67.45% in the past year. This is a very strong growth!
The Revenue has been growing by 238.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3806.9%
Revenue 1Y (TTM)67.45%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%-50.46%

3.2 Future

SALME is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 80.92% yearly.
The Revenue is expected to grow by 48.16% on average over the next years. This is a very strong growth
EPS Next Y109.36%
EPS Next 2Y74.45%
EPS Next 3Y92.99%
EPS Next 5Y80.92%
Revenue Next Year15.78%
Revenue Next 2Y30.97%
Revenue Next 3Y51.3%
Revenue Next 5Y48.16%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SALME.OL Yearly Revenue VS EstimatesSALME.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
SALME.OL Yearly EPS VS EstimatesSALME.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SALME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 53.06, which means the current valuation is very expensive for SALME.
Based on the Price/Forward Earnings ratio, SALME is valued a bit more expensive than 76.36% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 37.36. SALME is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 53.06
SALME.OL Price Earnings VS Forward Price EarningsSALME.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SALME is valued expensively inside the industry as 83.64% of the companies are valued cheaper.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 79.3
SALME.OL Per share dataSALME.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

SALME's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SALME's earnings are expected to grow with 92.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y74.45%
EPS Next 3Y92.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SALME!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SALMON EVOLUTION ASA

OSL:SALME (7/24/2025, 3:53:27 PM)

6.09

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-19 2025-08-19
Inst Owners21.67%
Inst Owner ChangeN/A
Ins Owners2.19%
Ins Owner ChangeN/A
Market Cap2.82B
Analysts85
Price Target9.21 (51.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-742.73%
Min EPS beat(2)-1265.05%
Max EPS beat(2)-220.42%
EPS beat(4)1
Avg EPS beat(4)-391.97%
Min EPS beat(4)-1265.05%
Max EPS beat(4)6.04%
EPS beat(8)2
Avg EPS beat(8)-212.49%
EPS beat(12)6
Avg EPS beat(12)-132.81%
EPS beat(16)9
Avg EPS beat(16)-97.7%
Revenue beat(2)1
Avg Revenue beat(2)-20.97%
Min Revenue beat(2)-43.93%
Max Revenue beat(2)1.98%
Revenue beat(4)1
Avg Revenue beat(4)-21.8%
Min Revenue beat(4)-43.93%
Max Revenue beat(4)1.98%
Revenue beat(8)3
Avg Revenue beat(8)-21.1%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.22%
PT rev (3m)-7.74%
EPS NQ rev (1m)-4.77%
EPS NQ rev (3m)-168.76%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-4.77%
Revenue NQ rev (3m)-35.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 53.06
P/S 6.71
P/FCF N/A
P/OCF 73.03
P/B 1.3
P/tB 1.35
EV/EBITDA 79.3
EPS(TTM)-0.22
EYN/A
EPS(NY)0.11
Fwd EY1.88%
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)0.08
OCFY1.37%
SpS0.91
BVpS4.69
TBVpS4.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.87%
ROE -4.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.28%
FCFM N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA 19.69
Cap/Depr 717.36%
Cap/Sales 135.14%
Interest Coverage N/A
Cash Conversion 89.28%
Profit Quality N/A
Current Ratio 1.8
Quick Ratio 1.29
Altman-Z 1.43
F-Score4
WACC7.97%
ROIC/WACCN/A
Cap/Depr(3y)4495.02%
Cap/Depr(5y)15899.7%
Cap/Sales(3y)642.51%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3806.9%
EPS Next Y109.36%
EPS Next 2Y74.45%
EPS Next 3Y92.99%
EPS Next 5Y80.92%
Revenue 1Y (TTM)67.45%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%-50.46%
Revenue Next Year15.78%
Revenue Next 2Y30.97%
Revenue Next 3Y51.3%
Revenue Next 5Y48.16%
EBIT growth 1Y64.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73454.1%
EBIT Next 3Y1493.28%
EBIT Next 5Y543.81%
FCF growth 1Y26.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.89%
OCF growth 3YN/A
OCF growth 5YN/A